Media Coverage

As more states legalize medicinal and recreational marijuana, more people are using the substance. In fact, a new report from Quest Diagnostics found that more people are testing positive for marijuana in workplace drug tests, with 2017 being the fifth year in a row for increased marijuana detection in urine drug tests. In 2017, 2.6% of the general workforce tested positive for marijuana use.

Quest Diagnostics, Secaucus, a provider of diagnostic information services, announced that it has completed the sale of its India medical diagnostic service business to Strand Life Sciences, a Bangalore-based specialized diagnostics company. Terms of this transaction were not disclosed. Alvarez & Marsal Corporate Finance & Restructuring, India acted as the exclusive financial advisor to Quest Diagnostics.

One of the largest U.S. drug-testing laboratories has analyzed its millions of urine drug test results by industry for the first time, and found the two industries with the highest rate of positive test results for marijuana were also two that have to deal with consumers. Some 5.3 percent of tests given to retail trade workers, and 4.7 percent of those given to health care and social assistance workers came back positive, according to an analysis by Quest Diagnostics.

Apple's health records project onboarded 100-plus hospitals and clinics. Apple has also been collaborating with national clinical testing labs — such as LabCorp and Quest Diagnostics — to bring patients' diagnostic results directly into the iPhone Health app as part of the health records feature.

Drug use by the U.S. workforce increased each year -- and by double-digits over two years -- between 2015 and 2017, in five of 16 major U.S. industry sectors analyzed, according to a first-ever analysis of industry-specific data from more than ten million urine drug test results performed by Quest Diagnostics, the world's leading provider of diagnostic information services.

Tapping its massive sample of over 10 million employee drug tests across the country, Quest Diagnostics said it's identified the industries in which the most workers test positive for drugs.

Palm Harbor, one of WhiteSands’ drug and alcohol rehabilitation facilities in Palm Harbor, FL, is happy to offer its services to patients with addiction problems. The company helps those with drug and alcohol addiction issues to get help and back on the road to recovery. Drug addiction is increasing according to Quest Diagnostics, one of the nation’s leading providers of employee drug testing when they reported that in September of 2015 the percentage of employees testing positive for drugs had reached a 10-year high.

These days, cannabidiol, or CBD, which is the non-inebriating compound in marijuana, is being used for pain, anxiety, and as a sleep aid. Also, the FDA recently approved its use for seizures associated with Lennox-Gastaut Syndrome and Dravet Syndrome, which are severe forms of epilepsy. At Quest Diagnostics, one of the biggest drug testing companies in the United States, they don’t offer testing for CBD and it’s not part of any employer drug testing program, says Barry Sample, director of science and technology for employer solutions at the company. Even people who are being drug tested for the DEA are not tested for CBD; in fact, federal employees can only be drug tested for certain predetermined compounds, and CBD isn’t one of them.

Aetna, a CVS Health business, and Ascension have joined the pilot project applying blockchain technology to improve data quality and reduce administrative costs associated with changes to health care provider demographic data. Humana, MultiPlan, Quest Diagnostics and UnitedHealth Groups Optum and UnitedHealthcare announced the launch of the Synaptic Health Alliance pilot project in April.

Protocol Testing is certified to perform individual, forensic and federally regulated drug and alcohol testing in their offices or at a place of business. Protocol performs urine, hair, nail, and alcohol testing (EtG and Breath) for: pre-employment, post-accident, reasonable suspicion, random, return to duty, follow-up, court ordered, students, probation and workers comp. We are also certified for Paternal DNA Testing. Rick told the group they use a variety of labs used for analysis which include Quest, Labcorp, Expertox, and USDTL.

Although it is crucial to identify tick-borne diseases, including Lyme, early, many tests can be inaccurate or difficult to interpret. Chromacode Inc., of Carlsbad, Calif., is looking to help change that. The company reported the commercial launch of its first multiplex test using its High Definition Polymerase Chain Reaction (HDPCR) technology. Chromacode said the HDPCR Tick-Borne Pathogen (TBP) panel is the only multiplex PCR test that detects nine of the most common tick-borne pathogens in a single test. This past summer, Quest Diagnostics Inc. helped put that in perspective after looking at more than 6 million de-identified laboratory test results over the past seven years and determining that the disease spiked between 2016 and 2017.

Workplace drug testing was jump-started by President Reagan’s 1986 executive order mandating it for federal employees. In 1988, Congress passed The Drug-Free Workplace Act (41 U.S.C. 81). This law requires some Federal contractors and all Federal grantees to agree that they will provide drug-free workplaces as a precondition of receiving a contract or grant from a Federal agency. Over 9.5 million urine drug tests were positive in the U.S. workforce in 2015. The rates increased to 4% of workers tested in 2015 versus 3.9% the year before, per Quest Diagnostics.

On Dec 5, we issued an updated research report on Quest Diagnostics, Inc.. The stock carries a Zacks Rank #3. Over the past three months, shares of this major commercial laboratory services provider have outperformed its industry. The stock has declined 18% compared with the industry’s 19.9% fall.

he boom of blockchain and distributed ledger technologies have inspired healthcare organizations to test the capabilities of their data. Quest Diagnostics, in partnership with Humana, MultiPlan, and UnitedHealth Group’s Optum and UnitedHealthcare, have launched a pilot program that applies blockchain technology to improve data quality and reduce administrative costs associated with changes to healthcare provider demographic data.

Quest Diagnostics recently announced it will contribute biomarker implementation, population health analytics and a national lab platform as a pillar supporter of One Brave Idea, the research initiative cofounded by the American Heart Association (AHA) and Verily Life Sciences with significant support from AstraZeneca. The company said it hopes to advance the work to identify coronary heart disease at the earliest transition from wellness to disease.

At 5.7 percent Louisiana’s drug test positivity rate is over 1 percent higher than the national average, according to a map produced by Quest Diagnostics' drug testing index.

Quest Diagnostics Inc (NYSE:DGX) institutional sentiment increased to 0.93 in Q2 2018. Its up 0.13, from 0.8 in 2018Q1. The ratio has increased, as 217 funds opened new and increased equity positions, while 234 cut down and sold their stakes in Quest Diagnostics Inc. The funds in our partner’s database reported: 110.90 million shares, down from 111.81 million shares in 2018Q1. Also, the number of funds holding Quest Diagnostics Inc in their top 10 equity positions increased from 0 to 3 for an increase of 3. Sold All: 30 Reduced: 204 Increased: 145 New Position: 72.

Dana-Farber Cancer Institute scientists will present research marking significant advances against the hematologic cancer multiple myeloma at the American Society of Hematology (ASH) Annual Meeting Dec. 1-4. Their findings provide new insights into the progression of the disease from precursor conditions and suggest approaches for novel treatments. Testing will be performed at each participant's local Quest Diagnostics laboratory. To sign up for the study, please visit http://www.promisestudy.org.

Aetna, a CVS Health business, and Ascension have joined the pilot project applying blockchain technology to improve data quality and reduce administrative costs associated with changes to health care provider demographic data. Humana, MultiPlan, Quest Diagnostics and UnitedHealth Group’s (NYSE: UNH) Optum and UnitedHealthcare announced the launch of the Synaptic Health Alliance pilot project in April.

Quest Diagnostics made it official: It is coming to the city and bringing 1,100 jobs. The company told officials it hopes to break ground for the 250,000-square-foot facility and accompanying five to seven-story parking garage this spring, officials said.

Quest Diagnostics Inc. (Quest), an American diagnostic information service provider, has reportedly announced that it has inked an agreement to acquire the laboratory services business unit belonging to Boyce and Bynum Pathology Laboratories (BBPL), a clinical & diagnostic laboratory service provider.

Parts of Boyce and Bynum Pathology Labs are set to be acquired by Quest Diagnostics. Quest announced they recently signed an agreement to acquire the assets of Boyce and Bynum's clinical laboratory services.

Quest Diagnostics announced today that it will build a 250,000-square-foot flagship laboratory in Clifton, New Jersey. The new laboratory will become the largest of the more than 20 major laboratory facilities in the Quest network and will employ more than 1,100 people. It is expected to be operational in early 2021.

The questions sound familiar: “Describe a time when you went above and beyond;” “Tell me about a time when you had to deliver bad news to a customer.” But in this telephone job interview, there is a twist: No human is on the other end of the line. Major companies such as laboratory-test provider Quest Diagnostics Inc., hospital operator HCA Healthcare Inc. and insurer Allstate Insurance Co. use such interviews for some hiring, as do retailers, restaurant chains and law firms.

Quest Diagnostics, the world's leading provider of diagnostic information services, today announced that it has signed a definitive agreement to acquire the assets of the clinical laboratory services business of Boyce and Bynum Pathology Laboratories (BBPL), a leading provider of diagnostic and clinical laboratory services in the Midwest.